Xeljanz is a medicine for some types of arthritis and for ulcerative colitis, a bowel disease. It is taken as a pill or a liquid by mouth. It works by calming parts of the immune system that cause swelling and pain.
Every report comes from a Lived member, sent anonymously.
Have you tried Xeljanz (Tofacitinib) for Rheumatoid Arthritis?
Tofacitinib, sold as Xeljanz and Xeljanz XR (extended-release), is a prescription pill that calms an overactive immune system. It treats several long-term inflammatory diseases in which the immune system attacks the body's own tissues. In adults, these are rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (inflammatory arthritis that mainly affects the spine) and moderately to severely active ulcerative colitis, an inflammatory disease of the large intestine. The tablets and a liquid form are also approved for children 2 and older with polyarticular juvenile idiopathic arthritis (childhood arthritis affecting many joints) or psoriatic arthritis. In the US, tofacitinib is approved only for people whose disease did not improve enough with, or who could not tolerate, at least one TNF (tumor necrosis factor) blocker. TNF blockers are injected or infused biologic medicines, such as adalimumab (Humira), that are commonly tried earlier. Tofacitinib was moved behind them because of safety concerns about heart problems, blood clots and cancer.
In these diseases, immune cells keep sending inflammatory signals through messenger proteins called cytokines. When a cytokine attaches to a cell, enzymes inside the cell called Janus kinases (JAKs) relay the message and switch on activity that drives inflammation. Tofacitinib is a JAK inhibitor: it blocks these enzymes, so many inflammatory signals are muted at once. The intended result is less joint pain, swelling and stiffness, or less inflammation in the lining of the colon. The same signaling pathways also help the body fight infection and make blood cells. That is why dampening them brings both the benefit and the main risks, such as more infections and changes in blood counts. Researchers do not know exactly which of the JAK pathways matter most for the benefit.
Xeljanz tablets are taken twice a day and Xeljanz XR (extended-release) tablets once a day, with or without food. For adults with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis, the usual dose is 5 mg twice a day or 11 mg of XR once a day. For psoriatic arthritis, it is taken together with a conventional arthritis medicine such as methotrexate, sulfasalazine or leflunomide. Children take the tablets or the oral solution at a dose based on body weight; the XR form is for adults only. Ulcerative colitis follows a different pattern. Treatment starts with a higher induction dose (10 mg twice a day, or 22 mg of XR once a day) for 8 weeks, sometimes extended to 16 weeks. If the colitis has not responded by then, the medicine is stopped. People who respond step down to a lower maintenance dose, though the higher dose is sometimes used again for a short time if the response fades. The higher dose carries more risk of serious infection, shingles and blood clots, so it is used for the shortest time needed, and it is not used for the arthritis conditions. Swallow XR tablets whole, without crushing, splitting or chewing. An empty tablet shell may show up in the stool; the medicine has already been absorbed by then. Lower doses may be needed with moderate or severe kidney disease, moderate liver disease or certain other medicines, and it is generally not used with severe liver disease. Switching between the twice-daily and once-daily forms should be done by the prescriber.
The most common side effects are colds and other upper respiratory infections, a stuffy nose or sore throat, diarrhea and headache. Some people develop higher blood pressure or acne. In ulcerative colitis, raised cholesterol, rash, a raised muscle enzyme (creatine phosphokinase) on blood tests, and shingles are also common. Shingles (herpes zoster) is a painful, blistering rash caused by the chickenpox virus reawakening, and it occurs more often with tofacitinib. Because tofacitinib weakens immune defenses, infections can become serious, including tuberculosis and fungal infections. Contact the care team right away (the same day) for signs of infection: fever, chills or sweats, a new or worsening cough, warm, red or painful skin, or burning when urinating. Stomach pain that does not go away (especially with fever or a change in bowel habits) and new weakness, vision changes or confusion also need a same-day call, since they can rarely signal a tear in the intestine or a serious brain infection. Two situations mean stopping the tablets and contacting the prescriber right away: swelling, pain or redness in one leg or arm, which can signal a clot in a vein, and hives or swelling of the face or lips without trouble breathing, which can signal an allergic reaction. Get emergency help for chest pain or pressure, sudden shortness of breath, weakness or drooping on one side of the body or face, slurred speech, or swelling of the lips, tongue or throat with trouble breathing or swallowing. These can signal a heart attack, stroke, blood clot in the lungs or severe allergic reaction.
Tofacitinib carries a boxed warning, the most serious kind of warning from the US Food and Drug Administration (FDA). A large study of adults 50 and older with rheumatoid arthritis and at least one heart disease risk factor compared tofacitinib with TNF blockers. In that group, people taking tofacitinib had more heart attacks and strokes, more blood clots in the lungs and veins, more cancers (particularly lung cancer and lymphoma, a cancer of immune cells) and more deaths from any cause than people taking a TNF blocker, and current or former smokers had additional risk. Serious, sometimes fatal infections are part of the same warning. The trade-off is weighed carefully for anyone who smokes or used to smoke, has heart disease risk factors, or has had a heart attack, stroke or cancer, and the medicine is stopped after a heart attack or stroke. Tofacitinib is generally avoided in people at higher risk of blood clots, including people who have had one. Tofacitinib should not be combined with biologic medicines for these conditions (such as adalimumab, etanercept or vedolizumab) or with strong immune-suppressing drugs such as azathioprine and cyclosporine, because the infection risk adds up. Some medicines change how much tofacitinib reaches the blood: the antifungals ketoconazole and fluconazole raise levels and call for a lower dose, while rifampin, an antibiotic used for tuberculosis, lowers levels and can make tofacitinib stop working, so the two are usually not used together. Live vaccines, made from weakened living germs, should be avoided during treatment, so vaccinations are best brought up to date before starting. A tear in the stomach or intestine is more likely in people with diverticulitis (inflamed pouches in the wall of the colon) or ulcers, or who also take anti-inflammatory painkillers such as ibuprofen or naproxen, steroids or methotrexate. People with diabetes may need to check blood sugar more often, since low blood sugar has been reported. There is not enough human data to know whether tofacitinib harms a developing baby, and animal studies showed harm at high exposures. It may also reduce fertility in women, and it is not known whether that reverses. Breastfeeding is not recommended during treatment and for at least 18 hours after the last tablet or liquid dose (36 hours after XR). Anyone pregnant or planning a pregnancy should discuss the plan with the prescriber.
Before starting, expect a tuberculosis test, screening for hepatitis B and C (viruses that can flare up when the immune system is suppressed), a complete blood count and a review of vaccinations. Inactive (latent) tuberculosis is treated before tofacitinib begins, and watching for tuberculosis continues during treatment even after a negative first test. Treatment is not started during an active serious infection and is paused if one develops. Blood tests repeat during treatment to check white and red blood cell counts and liver tests, and cholesterol is checked about 4 to 8 weeks after starting. Treatment may be paused if counts fall too low. People at higher risk of skin cancer are advised to have periodic skin checks. In rheumatoid arthritis, the aim is less joint pain, swelling and stiffness and easier day-to-day function. In trials, more people improved than with a placebo (an inactive pill) as early as 2 weeks, and the benefit was still clear at 3 and 6 months, so it can take a few months to judge the full effect. In ulcerative colitis, the induction phase lasts at least 8 weeks: in the main trial, 18 in 100 people were in remission at that point (no rectal bleeding, few or no other symptoms, and a colon lining close to normal on a scope examination), compared with 8 in 100 on placebo, with lower rates in people whose TNF blocker had failed. Among people who responded, about a third of those on the 5 mg twice-daily maintenance dose were in remission at one year, compared with about 1 in 10 on placebo. Response varies, and some people do not benefit enough to continue. Because the risks of tofacitinib are ongoing, whether to keep taking it is worth revisiting at follow-up visits, especially if heart risk factors, smoking or other health conditions change.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Xeljanz (Tofacitinib), what you've noticed, or ask the community a question.